Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The current ratio is N/A as of Tuesday, October 6, 2026.
CURRENT RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$978.09M
Current Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Current Ratio
5.04
TTM Avg
3.47
3Y Avg
3.89
5Y Avg
3.30
Market Cap
$982.46M
Current Ratio
15.08
TTM Avg
22.50
3Y Avg
27.08
5Y Avg
27.08
Market Cap
$996.65M
Current Ratio
6.55
TTM Avg
7.96
3Y Avg
7.82
5Y Avg
9.82
Market Cap
$998.69M
Current Ratio
8.42
TTM Avg
11.89
3Y Avg
15.48
5Y Avg
17.00
Market Cap
$953.81M
Current Ratio
16.33
TTM Avg
11.68
3Y Avg
16.13
5Y Avg
16.13
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 3.76 | 1.39 | 1.76 | 2.46 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 5.04 | 3.47 | 3.89 | 3.30 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 15.08 | 22.50 | 27.08 | 27.08 |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 19.15 | 11.70 | 12.62 | 12.74 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 6.55 | 7.96 | 7.82 | 9.82 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 8.42 | 11.89 | 15.48 | 17.00 |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | 16.33 | 11.68 | 16.13 | 16.13 |
| Savara Inc. (SVRA)vs › | $952.91M | 10.13 | 12.79 | 15.81 | 14.15 |
| Immatics N.V. (IMTX)vs › | $1.01B | 7.54 | 10.49 | 6.85 | 5.34 |
Current Ratio
N/A
Quick Ratio
N/A
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
